Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 3 and Insertion of the selection cassette in exon 3.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-GMNN, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Geminin also referred to as GMNN is a protein that regulates DNA replication. It has approximately 25 kDa mass. Geminin inhibits DNA replication by preventing the loading of the mini-chromosome maintenance complex onto DNA during the cell cycle. This function ensures that DNA replication takes place only once per cell cycle. Geminin expresses mainly in tissues with high proliferative activity such as the developing nervous system and hematopoietic cells. Its interaction with other proteins plays a significant role in controlling cell cycle progression.
Biological function summary
In a cellular context Geminin forms part of a complex with the nuclear protein Cdt1. This complex is essential in the regulation of the cell cycle's S phase. Geminin's function restricts DNA replication by binding to Cdt1 and stopping its activity which is necessary during the G1/S phase transition. By doing so it preserves the integrity of genetic information and prevents re-replication. Geminin's inhibition remains strict until it is degraded during mitosis allowing Cdt1 to resume its function in the following cell cycle.
Pathways
The regulation of Geminin is important to maintaining proper DNA replication and cell cycle integrity. Geminin plays a role in the cell cycle control pathway particularly during the G1 to S phase transition. Additionally it interfaces with other proteins like Paxillin which is involved in cell adhesion and movement. Although not directly linked in a pathway Paxillin's role in regulating cellular dynamics can influence cell cycle processes in which Geminin is involved. Geminin also serves as a K blocker relevant in maintaining genetic stability.
Aberrations in Geminin activity can lead to severe conditions such as cancer. Its overexpression or misregulation has a link to various tumor types due to its effect on uncontrolled cell proliferation. Geminin's interaction with proteins like Paxillin and Cyclin-dependent kinases also relates to cancer progression as these interactions may involve changes in cellular adhesion and cycle checkpoints. Therefore understanding Geminin's role offers valuable insight for potential therapeutic targets in oncology.
